Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUTI vaccine in pulmonary tuberculosis
NCT05455112Phase 2Completed
- Sponsor
- Archivel Farma
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing RUTI with Placebo (2 arms). Primary endpoints: Early Bactericidal Activity 0-14 days, Adverse Events at 24 weeks and 1 more. Started Oct 2022; status: completed.
02
Drugs
RUTI vaccine
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT05455112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05455112.